Gabelli Funds LLC Lowers Stake in Anterix Inc. (NASDAQ:ATEX)

Gabelli Funds LLC reduced its holdings in shares of Anterix Inc. (NASDAQ:ATEXFree Report) by 0.7% in the first quarter, HoldingsChannel reports. The fund owned 134,100 shares of the company’s stock after selling 1,000 shares during the period. Gabelli Funds LLC’s holdings in Anterix were worth $4,507,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Heard Capital LLC raised its holdings in Anterix by 0.9% in the fourth quarter. Heard Capital LLC now owns 1,829,551 shares of the company’s stock worth $60,961,000 after buying an additional 16,420 shares during the last quarter. Vanguard Group Inc. raised its holdings in Anterix by 0.9% in the first quarter. Vanguard Group Inc. now owns 876,015 shares of the company’s stock worth $29,443,000 after buying an additional 8,020 shares during the last quarter. Clearbridge Investments LLC raised its holdings in Anterix by 2.2% in the first quarter. Clearbridge Investments LLC now owns 318,021 shares of the company’s stock worth $10,689,000 after buying an additional 6,844 shares during the last quarter. Roubaix Capital LLC raised its holdings in Anterix by 7.0% in the first quarter. Roubaix Capital LLC now owns 178,543 shares of the company’s stock worth $6,001,000 after buying an additional 11,666 shares during the last quarter. Finally, Kirr Marbach & Co. LLC IN raised its holdings in Anterix by 54.2% in the fourth quarter. Kirr Marbach & Co. LLC IN now owns 97,985 shares of the company’s stock worth $3,265,000 after buying an additional 34,425 shares during the last quarter. 87.67% of the stock is owned by hedge funds and other institutional investors.

Anterix Stock Up 1.0 %

Anterix stock traded up $0.39 during trading hours on Friday, hitting $40.27. The stock had a trading volume of 56,560 shares, compared to its average volume of 166,813. The stock has a market capitalization of $747.81 million, a P/E ratio of -82.18 and a beta of 0.86. Anterix Inc. has a 12-month low of $27.20 and a 12-month high of $42.41. The stock’s 50-day moving average price is $35.52 and its 200-day moving average price is $33.98.

Anterix (NASDAQ:ATEXGet Free Report) last announced its quarterly earnings results on Wednesday, June 26th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.27). Anterix had a negative return on equity of 18.84% and a negative net margin of 217.80%. The company had revenue of $1.26 million during the quarter, compared to the consensus estimate of $1.52 million. On average, research analysts expect that Anterix Inc. will post -2.02 EPS for the current fiscal year.

Insider Transactions at Anterix

In other news, CFO Timothy Gray sold 16,667 shares of Anterix stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $31.91, for a total value of $531,843.97. Following the completion of the sale, the chief financial officer now directly owns 90,475 shares in the company, valued at $2,887,057.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 45.61% of the company’s stock.

About Anterix

(Free Report)

Anterix Inc operates as a wireless communications company. The company focuses on commercializing its spectrum assets to enable the targeted utility and critical infrastructure customers to deploy private broadband networks and innovative broadband solutions. It holds licensed spectrum in the 900 MHz band with coverage throughout the United States, Alaska, Hawaii, and Puerto Rico.

Read More

Want to see what other hedge funds are holding ATEX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anterix Inc. (NASDAQ:ATEXFree Report).

Institutional Ownership by Quarter for Anterix (NASDAQ:ATEX)

Receive News & Ratings for Anterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anterix and related companies with MarketBeat.com's FREE daily email newsletter.